-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UXDWROEJXre/usphMWXkTyXHt5pGVZAxX4ify6Dk97qRTEIo4hjfhQVOYNMCCO8h x/gRuvQ6klF12t5ilnZxCQ== 0000936392-99-000653.txt : 19990624 0000936392-99-000653.hdr.sgml : 19990624 ACCESSION NUMBER: 0000936392-99-000653 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19990526 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19990528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-24274 FILM NUMBER: 99637589 BUSINESS ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194526600 MAIL ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 FORM 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 26, 1999 LA JOLLA PHARMACEUTICAL COMPANY - -------------------------------------------------------------------------------- (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 0-24274 33-0361285 - -------------------------------------------------------------------------------- (STATE OR OTHER (COMMISSION (I.R.S. EMPLOYER JURISDICTION OF FILE NUMBER) IDENTIFICATION NO.) INCORPORATION) 6455 Nancy Ridge Drive San Diego, CA 92121 - -------------------------------------------------------------------------------- (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE) REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (619) 452-6600 - -------------------------------------------------------------------------------- (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT) 2 ITEM 5. OTHER EVENTS On May 26, 1999, La Jolla Pharmaceutical Company issued a press release announcing the extension by one year of the life of the Company's warrants and an option, granted to the underwriter of the Company's initial public offering, to purchase shares of the Company's common stock and warrants. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS Pursuant to General Instruction F of Form 8-K, the following document is incorporated by reference herein and attached as an exhibit hereto:
EXHIBIT DESCRIPTION ------- ----------- 99.1 La Jolla Pharmaceutical Company press release of May 26, 1999 regarding the Company's extension by one year of the life of the Company's warrants and an underwriter option to purchase shares of the Company's common stock and warrants.
3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. La Jolla Pharmaceutical Company (Registrant) Date: May 27, 1999 By: /s/ Wood C. Erwin ------------------------------------ (Signature) Name: Wood C. Erwin Title: Chief Financial Officer 4 LA JOLLA PHARMACEUTICAL COMPANY INDEX TO EXHIBITS
EXHIBIT NUMBER EXHIBIT - ------- ------- 99.1 La Jolla Pharmaceutical Company press release of May 26, 1999 regarding the Company's extension by one year of the life of the Company's warrants and an underwriter option to purchase shares of the Company's common stock and warrants.
EX-99.1 2 EXHIBIT 99.1 1 EXHIBIT 99.1 May 26, 1999 Richard Krawiec, Ph.D., Vice President, Investor Relations LA JOLLA PHARMACEUTICAL EXTENDS LIFE OF WARRANTS BY ONE YEAR San Diego, CA - May 26, 1999 - La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that it has decided to extend by one year the life of all Company warrants and an option granted to the underwriter of the Company's initial public offering to purchase additional shares of the Company's common stock and warrants. All warrants to purchase shares of Company common stock and the underwriter's option had been set to expire on June 3, 1999. The warrants and underwriter's option will be exercisable at any time until June 3, 2000. The remaining terms of the Company's public warrants (LJPCW), including the exercise price of $3.00 per one half share, and the remaining terms of the Company's other warrants and the underwriter's option, including exercise prices, remain unchanged and are explained in La Jolla Pharmaceutical Company's Securities and Exchange Commission filings on Form 10-K for the year ended December 31, 1998. San Diego-based La Jolla Pharmaceutical Company develops disease-specific therapeutics using its proprietary Tolerance Technology(R) for major diseases and conditions caused by antibodies such as lupus, antibody-mediated stroke, myocardial infarction, deep vein thrombosis, recurrent fetal loss, organ rejection in xenotransplantation, Rh hemolytic disease, and myasthenia gravis. Toleragens(R) under development by La Jolla Pharmaceutical are designed to reduce the levels of disease-causing antibodies in patients suffering from these conditions. The Company's common stock and public warrants trade on The Nasdaq Stock Market under the symbols LJPC and LJPCW, respectively. For more information about the Company, visit our web site: www.ljpc.com. Some of the statements in this press release discuss future expectations, contain projections or state other forward-looking information. These statements involve risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to be materially different from those contemplated by the forward-looking statements. Interested parties are urged to review the risks detailed from time to time in La Jolla Pharmaceutical Company's Securities and Exchange Commission (SEC) filings, including the report on Form 10-K for the year ended December 31, 1998 and the report on Form 10-Q for the first quarter ended March 31, 1999. #### -----END PRIVACY-ENHANCED MESSAGE-----